Is Ginkgo Bioworks profitable in 2026?

No. Ginkgo posted a Q1 2026 net loss from continuing operations of -$76 million on revenue of just $19 million, down 49% year over year from $38 million in Q1 2025, missing consensus estimates of $42.93 million, as of March 31, 2026.

Could AI replace Ginkgo Bioworks?

Possibly at the platform level. Ginkgo is an integrated wet-lab partner inside Amazon's Bio Discovery platform as disclosed in May 2026, but AWS, Google Cloud, and OpenAI are simultaneously partners and structurally unbarred from building proprietary autonomous-lab capability in-house, making Ginkgo a replaceable node rather than a gatekeeper.

Who is Ginkgo Bioworks' biggest competitor?

CEO Jason Kelly has cited new Silicon Valley autonomous-lab entrants as competitive pressure (May 2026 earnings call), alongside cloud/AI giants AWS, Google Cloud, and OpenAI, and traditional CRO lab-services arms like Charles River Laboratories and Thermo Fisher Scientific.

Who owns Ginkgo Bioworks?

Ginkgo Bioworks is a publicly traded company on NYSE under ticker DNA with no parent company. Baillie Gifford became its largest shareholder at roughly 15% in March 2022, after Ginkgo went public via SPAC merger at a reported $17.5 billion valuation on September 17, 2021.

Will Ginkgo Bioworks run out of cash?

Ginkgo held $373 million in cash as of March 31, 2026, down from $423 million at end of 2025, against reaffirmed 2026 cash-burn guidance of $125 to $150 million, implying roughly a 2.5 to 3 year runway before it likely needs a dilutive capital raise.

Why did Ginkgo Bioworks stock crash in 2026?

DNA's market cap fell to about $516.7 million by July 20, 2026, down over 95% from its 2021 peak, as Wall Street Zen downgraded the stock to Sell on July 18, 2026 and BTIG cut its price target from $9 to $5, citing collapsing revenue during the autonomous-lab pivot.

AI companies and labs · United States

Ginkgo Bioworks

ginkgobioworks.com ↗

Sells AI-run lab automation and biological data to drug and industrial firms.

Losing its protection

Assessed 21 July 2026 · Evidence as of 21 July 2026

The structural protection is eroding.

On the recordSince 21 July 2026 · Checkable from August 6, 2026 · Every call on the record Checkpoint: Q2 2026 earnings report, key test of whether autonomous lab revenue stabilizes

The call

Ginkgo has real automation and data assets but revenue keeps shrinking while cash burns toward a raise that could wipe out current shareholders.

Ginkgo Bioworks designs robot laboratories that use artificial intelligence to run biological experiments automatically, and sells access to these labs plus data software to drug companies. The problem is that large established companies like Charles River Laboratories and Thermo Fisher can build the same robot labs themselves, and tech giants like Amazon Web Services and Google could do it too since Ginkgo is currently just a partner feeding data into their platforms. The company only has 2.5 to 3 years of cash left, which means it will probably need to raise money soon at a much lower valuation, wiping out investor gains. What matters most is whether Ginkgo's data and cloud software actually start making money in the next two quarters instead of continuing to lose revenue, or whether the tech giants decide to build their own autonomous labs in-house and stop needing Ginkgo altogether.

Why

AI pressure: AWS Bio Discovery, Google Cloud, OpenAI. Cloud and AI partners currently buy Ginkgo's lab services but face no barrier to building their own autonomous labs in house. Could AI do the core job? Yes, likely.

Bigger players: Charles River Laboratories, Thermo Fisher Scientific. Bigger CROs with existing pharma contracts and physical lab scale can add automation faster than Ginkgo can add pharma relationships. Could a giant copy it? Yes, easily.

What protects it. Its Datapoints biological data library and Nebula lab integrations are hard to copy quickly, but not yet generating growth.

What would change this call

Q2 2026 earnings (~Aug 6, 2026) show whether Datapoints/Cloud Lab revenue grows or keeps declining. Tests if the autonomous-lab pivot is reversing the revenue collapse or not.
Whether Ginkgo announces a dilutive capital raise given ~2.5 year runway at current burn. Would show cash pressure is forcing equity dilution, weakening shareholder position.
Whether AWS, Google Cloud, or OpenAI build in-house autonomous-lab capability instead of using Ginkgo. Would show partners becoming competitors and Ginkgo's role shrinking.

Key numbers

Q1 2026 revenue fell 49% YoY to $19M (2026-03-31)
Cash reserves at $373M, down from $423M (2026-03-31)
Market cap near $517M, down 95%+ from 2021 peak (2026-07-20)

Named risks

Cash runway of only 2.5 to 3 years may force a dilutive capital raise. Severity: high
Revenue collapsed 49% YoY in Q1 2026 despite the autonomous-lab pivot. Severity: high
No structural moat prevents CROs or cloud giants from replicating autonomous labs. Severity: high
Cloud/AI partners AWS, Google, OpenAI could shift from partner to in-house competitor. Severity: medium
Deteriorating analyst sentiment with Sell ratings and falling price targets in 2026. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Charles River Laboratories	contesting	Vastly larger physical CRO infrastructure with no automation P&L conflict, cited 2026
Thermo Fisher Scientific	contesting	Larger lab-services arm able to replicate autonomous lab capability, cited 2026
Amazon (AWS)	losing to	Ginkgo is a replaceable wet-lab node inside Amazon Bio Discovery platform, disclosed May 2026
OpenAI	contesting	Current partner but structurally free to build in-house autonomous lab tech, cited May 2026
Google Cloud	contesting	Ginkgo cut future cloud commitments over $100M in renegotiated deal, April 2026
Silicon Valley autonomous-lab startups	gaining on	CEO Kelly named new entrants as competitive pressure on Q1 2026 earnings call

Questions people ask

Is Ginkgo Bioworks profitable in 2026?: No. Ginkgo posted a Q1 2026 net loss from continuing operations of -$76 million on revenue of just $19 million, down 49% year over year from $38 million in Q1 2025, missing consensus estimates of $42.93 million, as of March 31, 2026.
Could AI replace Ginkgo Bioworks?: Possibly at the platform level. Ginkgo is an integrated wet-lab partner inside Amazon's Bio Discovery platform as disclosed in May 2026, but AWS, Google Cloud, and OpenAI are simultaneously partners and structurally unbarred from building proprietary autonomous-lab capability in-house, making Ginkgo a replaceable node rather than a gatekeeper.
Who is Ginkgo Bioworks' biggest competitor?: CEO Jason Kelly has cited new Silicon Valley autonomous-lab entrants as competitive pressure (May 2026 earnings call), alongside cloud/AI giants AWS, Google Cloud, and OpenAI, and traditional CRO lab-services arms like Charles River Laboratories and Thermo Fisher Scientific.
Who owns Ginkgo Bioworks?: Ginkgo Bioworks is a publicly traded company on NYSE under ticker DNA with no parent company. Baillie Gifford became its largest shareholder at roughly 15% in March 2022, after Ginkgo went public via SPAC merger at a reported $17.5 billion valuation on September 17, 2021.
Will Ginkgo Bioworks run out of cash?: Ginkgo held $373 million in cash as of March 31, 2026, down from $423 million at end of 2025, against reaffirmed 2026 cash-burn guidance of $125 to $150 million, implying roughly a 2.5 to 3 year runway before it likely needs a dilutive capital raise.
Why did Ginkgo Bioworks stock crash in 2026?: DNA's market cap fell to about $516.7 million by July 20, 2026, down over 95% from its 2021 peak, as Wall Street Zen downgraded the stock to Sell on July 18, 2026 and BTIG cut its price target from $9 to $5, citing collapsing revenue during the autonomous-lab pivot.

Timeline

2026-07-20Market cap roughly $516.7 million, stock trading $7.55-$8.29
2026-07-18Wall Street Zen downgrades DNA from Hold to Sell
2026-07-17Shares fall 6.7% in a single session
2026-05-07Q1 2026 results: revenue $19M, down 49% YoY, cash $373M
2026-04-07Completes divestiture of Biosecurity unit for ~20% stake in Perimeter Systems
2026-04-06Renegotiates Google Cloud deal, cutting commitments by over $100M
2026-02-26FY2025 earnings announce pivot to autonomous labs and Biosecurity sale plan
2022-07Acquires rival Zymergen in $300 million all-stock deal
2021-09-17Goes public via SPAC merger with Soaring Eagle at $17.5B valuation

Revision history

21 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Safe Superintelligence Inc.Mistral AI Cohere